Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

NCT00310232 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
70
Enrollment
OTHER
Sponsor class

Stopped Recommendation of DSMB for safety issue, increased mortality with study drug.

Conditions

Interventions

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators